Published: 2019-10-14 03:19:37
SUMMARY
Approximately
400,000 Americans are newly diagnosed with some type of brain tumor each
year. For decades, clinicians have sought better treatments for these
patients that would effectively target tumor cells while preserving
healthy tissue, but to no avail. There have been few new effective
therapies over the past 30 years, and outcomes for patients have improved
very little during this time. Recurrence of brain tumors is common, and
about half of all patients treated for brain tumors have their disease
recur within a year. As a result, patients often run out of treatment
options when their tumors reoccur. GT MedTech is a medical technology
company passionately committed to improving the lives of patients with
brain tumors. This company is an excellent example of how the combination
of leading edge research and development combined with an experienced
management team can move a company forward faster.
https://www.azbio.org/gt-medical-technologies-inc-to-be-honored-with-an-azbio-fast-lane-award